GlassScriptPhysician profile
Thomas J Svete
NPI 1598736332
$3,401.74
in general payments reported to CMS, 2019-2025
21 companies · $157 in 2025
The $157 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,403 · 2020: $150 · 2021: $82.65 · 2022: $73.76 · 2023: $389 · 2024: $147 · 2025: $157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $665 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $665.24 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $1,435.70 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $311.09 | 2021-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $241.86 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $200.03 | 2019-2020 | |
| Abbvie INC. | $169.49 | 2021-2023 | Vraylar |
| Janssen Pharmaceuticals, INC | $166.69 | 2019-2020 | |
| Axsome Therapeutics, INC. | $162.79 | 2023 | Auvelity |
| Vanda Pharmaceuticals INC. | $154.68 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $146.69 | 2024 | Cobenfy |
| Lundbeck LLC | $90.19 | 2019 | |
| Shire North American Group INC | $80.05 | 2019 | |
| Alkermes, INC. | $43.29 | 2023-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $43.13 | 2019 | |
| Avanir Pharmaceuticals, INC. | $42.05 | 2019 | |
| Bausch Health US, LLC | $38.68 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $20.16 | 2019 | |
| Adlon Therapeutics L.P. | $15.92 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.57 | 2023 | Austedo Xr |
| Arbor Pharmaceuticals, INC. | $12.17 | 2019 | |
| Neos Therapeutics, LP | $11.21 | 2020 | |
| Validus Pharmaceuticals LLC | $0.30 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Svete listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.